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Leiomyosarcoma (LMS) is a malignant, soft-tissue tumor for which few eﬀective therapies exist. Previously, we showed that
there are three molecular subtypes of LMS. Here, we analyzed genes diﬀerentially expressed in each of the three LMS subtypes
as compared to benign leiomyomas and then used the Connectivity Map (cmap) to calculate enrichment scores for the 1309 cmap
drugs in order to identify candidate molecules with the potential to induce a benign, leiomyoma-like phenotype in LMS cells. 11
drugs were selected and tested for their ability to inhibit the growth of three human LMS cell lines. We identiﬁed two drugs with
in vitro eﬃcacy against LMS, one of which had a strongly negative enrichment score (Cantharidin) and the other of which had a
strongly positive enrichment score (MG-132). Given MG-132’s strong inhibitory eﬀect on LMS cell viability, we hypothesized that
LMScellsmaybesensitivetotreatmentwithotherproteasomeinhibitorsanddemonstratedthatbortezomib,aclinically-approved
proteasome inhibitor not included in the original cmap screen, potently inhibited the viability of the LMS cell lines. These ﬁndings
suggest that systematically linking LMS subtype-speciﬁc expression signatures with drug-associated expression proﬁles represents
a promising approach for the identiﬁcation of new drugs for LMS.
1.Introduction
Leiomyosarcoma (LMS) is a malignant neoplasm of smooth
muscle that accounts for approximately one quarter of all
soft-tissue sarcomas. Most frequently, LMS occurs in the
uterus or the retroperitoneum, but these tumors can also
present in a number of soft tissues throughout the body.
Current treatment protocols for LMS consist of surgery
with adjuvant doxorubicin-based chemotherapy [1]. There
are no eﬀective targeted therapies available for this cancer.
Previously, using gene expression proﬁling, array compara-
tivehybridization, andimmunohistochemistry, weidentiﬁed
three distinct biologic subtypes of LMS [2] .T h ep r e s e n c eo f
distinctbiologicdiseasesubtypessuggeststhatLMSsubtypes
may show diﬀerential drug responses.
Leiomyoma (LM) is a benign smooth muscle neoplasm
that, like its malignant counterpart LMS, frequently occurs
in the uterus. While LM is a signiﬁcant cause of hospital-
izations for gynecological disorders and is the most frequent
reason for hysterectomies among US women, these growths
virtually never metastasize [3]. We hypothesize that genes
diﬀerentially expressed between LMS subtypes and LM may
provide insight into biological pathways driving malignant
behavior in LMS and may facilitate identiﬁcation of drugs to
target oncogenic pathways in LMS subtypes.
Here, we aimed to identify and validate new therapeutic
molecules for LMS. To do so, we identiﬁed genes that were
most highly diﬀerentially expressed between LM and each of
the three LMS subtypes. We then correlated these expression2 Sarcoma
proﬁles with the Connectivity Map (cmap), a reference
collection of gene expression proﬁles from cultured human
cell lines (breast cancer epithelial cell line MCF7, prostate
cancer cells PC3, leukemia cells HL60, and melanoma cells
SKMEL5) treated with a large and diverse library of small
molecules [4, 5]. Previous studies in cancer used cmap to
identify drugs with highly negative enrichment scores with
cancer signatures, hypothesizing that these molecules were
themostlikelytoshowtherapeuticeﬃcacyinthecancertype
[6–8].Similarly,weusedcmaptogenerateenrichmentscores
to indicate the direction and magnitude of the similarity
between each LMS subtype expression signature and each
drug’s eﬀect on gene expression in cancer cell lines. After
generating enrichment scores for each drug in cmap with
each of the three LMS subtype signatures, we selected
11 drugs (representing a range of enrichment scores) and
evaluated each drug’s ability to inhibit the viability of three
human LMS cell lines in vitro (Figure 1).
2. Results
LMS Subtype Signatures. To generate gene signatures of
each LMS subtype, we performed Signiﬁcance Analysis of
Microarrays [9] and identiﬁed the top 100 gene expression
features overexpressed in each LMS subtype and the top
100 gene expression features underexpressed in each subtype
compared with 19 leiomyoma samples. The gene expression
features were mapped to Aﬀymetrix probe IDs, and features
without probe IDs were excluded from the subsequent
analysis.
PredictionofNovelDrugsforLMS. Toidentifydrugstotarget
the diﬀerent LMS subtypes, we utilized the Connectivity
Map (cmap, http://www.broad.mit.edu/cmap/), which is a
publically available resource designed to ﬁnd connections
between disease-associated gene expression signatures and
drug response signatures [4, 5]. We uploaded the LMS
subtype gene signatures to cmap and generated enrichment
scores for each of the 1309 “perturbagens” in cmap. A
perturbagen is an agent (small molecule, genetic reagent,
etc.) that can be used to produce gene expression changes
in cell lines. The enrichment score is a value between
+1 and −1, and a high positive score indicates that the
perturbagen tended to induce the expression of the query
LMS subtype signature, while a high negative score indicates
theperturbagentendedtoreversetheexpressionofthequery
LMS subtype signature. Additional description of the cmap
procedure can be found in the methods and are discussed in
greater detail elsewhere [4].
Thisanalysisdemonstratedthattheperturbagensshowed
highly variable connectivity with the 3 LMS subtypes
(Figure 2, Supplemental Table S4 of the supplementary
material available online at doi:10.1155/2012/805614). Can-
tharidin showed the strongest negative enrichment scores
across the three LMS subtypes. Cantharidin is a drug from
traditional Chinese medicine, which has been predicted to
have anticancer activities through its activity as a protein
phosphatase inhibitor [10–12].
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Figure 1: Overview of analytical and experimental workﬂow. Gene
expression proﬁles from each of the three LMS subtypes were
compared to gene expression proﬁles from LM to identify the top
100 “up” and top 100 “down” diﬀerentially expressed genes for each
subtype compared with LM. These three pairs of gene lists were
then uploaded to cmap to estimate cmap enrichment scores linking
drugs with LMS subtype expression signatures. 11 drugs, with a
range of cmap enrichment scores, were then tested against three
LMS cell lines using in vitro drug response experiments.
The top ranking drugs with the most negative enrich-
ment scores in LMS Subtypes I and II included inhibitors of
known oncogenic pathways: Tyrphostin AG-825, a selective
tyrosine kinase inhibitor preferentially inhibiting HER-
2/neu, and geﬁtinib, an EGFR inhibitor. The top-ranking
drug with the most negative enrichment scores in LMS
SubtypeIIIwasMG132,aproteasomeinhibitor[13].MG132
achieved a high positive score in LMS Subtype II.Sarcoma 3
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Figure 2: Connectivity Map to identify drugs to target leiomyosar-
coma subtypes. Unsupervised hierarchical clustering of the drugs
(along the y-axis) and three LMS subtypes (along the x-axis).
The heatmap displays the enrichment score of each drug with
each LMS subtype. Green indicates negative enrichment and red
indicates positive enrichment. We used these data to test whether
the direction and/or magnitude of cmap enrichment scores could
predict drug response in LMS cell lines. Full results from the
Connectivity Map analysis are provided in Supplemental Table S4.
2.1. Subtyping LMS Cell Lines. We ﬁrst evaluated the sim-
ilarity of the LMS03, LMS04, and LMS05 cell lines to
expression proﬁles of the previously deﬁned LMS subtypes
using a nearest centroid analysis, in which we computed
gene expression centroids for each of the 3 LMS subtypes.
We found that all 3 cell lines most closely resembled the
LMSsubtypeIIcentroid(Figure 3(a)).Wenextevaluatedthe
mRNA expression levels of previously deﬁned LMS subtype
I-, II-, and III-speciﬁc genes in the three LMS cell lines.
Similar to our nearest centroid analysis results, all three
LMS cell lines showed a higher average expression of genes
associated with LMS subtype II in comparison to genes
associated with LMS subtypes I and III (Figure 3(b)).
2.2. Experimental Validation of Cmap Drugs. We next sought
to functionally validate our cmap predictions for novel
LMS drugs by performing in vitro cell viability assays using
three human LMS cell lines, LMS03, LMS04, and LMS05.
First, we selected 11 commercially available drugs with
cmap enrichment scores to an LMS subtype ranging from
approximately −1t o1( Table 1). While these drugs do
represent a range of enrichment scores, the set of drugs
evaluated was highly enriched for drugs with enrichment
scores near 1 or −1 (Median of absolute value of enrichment
score for 1309 perturbagens in cmap = 0 . 4v e r s u s0 . 7 9f o rt h e
11 drugs evaluated; Wilcoxon P = 0.00009 (Supplemental
F i g u r e1 ) ) .N e x t ,w et r e a t e dt h eL M Sc e l ll i n e sw i t he a c h
drug for 72 hours, using a concentration range of 0μMt o
10μM, before assessing cell viability (Figure 4). While most
drugs failed to potently inhibit cell viability in all three
LMS cell lines, both Cantharidin and MG132 demonstrated
strong antigrowth eﬀects across LMS03, LMS04, and LMS05
(Figures 4(b) and 4(j)).
Given MG132’s strong inhibitory eﬀect on LMS cell
viability,wehypothesizedthatLMScelllinesmaybesensitive
totreatmentwithotherproteasomeinhibitors.Therefore,we
evaluated the antigrowth eﬀects of bortezomib, a clinically
approved proteasome inhibitor that was not included in the
original cmap screen. After 72 hours of treatment using
a concentration range of 0μMt o1 0 μM, we found that
bortezomib could inhibit the viability of all three LMS cell
lines at doses as low as 0.04μM( Figure 5).
2.3. Evaluating Relationship between Cmap Enrichment Score
and LMS Drug Response. To determine whether cmap
enrichment scores were associated with in vitro drug
responseasmeasuredbyLMScelllineviability,wecalculated
the Pearson correlation between the percent inhibition of
cell viability at 10μM in LMS03, LMS04, and LMS05 for
each drug and the cmap enrichment scores determined for
all three LMS subtypes. Regardless of the cmap enrichment
scores used (subtype I, II, or III), we found no statistically
signiﬁcant association between in vitro drug response and
cmap enrichment scores (Supplemental Table S1). To ascer-
tain whether the magnitude of cmap enrichment, and not
the positivity or negativity of the score, was predictive of in
vitro drug response, we similarly calculated the correlation
between cell viability and cmap scores, this time using
only the absolute value of the cmap enrichment scores.
Similarly, we found no statistically signiﬁcant overall associ-
ation between the magnitude of a drug’s cmap enrichment
score and its ability to inhibit in vitro LMS cell viability
(Supplemental Table S2).
To speciﬁcally evaluate whether highly nonzero enrich-
ment (absolute value >0.75) were associated with in vitro
drug response as a binary variable, we performed a Fisher’s
exact test where a signiﬁcant cmap enrichment score was
deﬁned as having an absolute value greater than 0.75 and a
signiﬁcant drug response was deﬁned as having greater than4 Sarcoma
Table 1: Mechanisms of action and cmap enrichment scores for drugs tested in LMS cell lines.
Drug name Mechanism of action Clinical use
LMS I
cmap
score
LMS II
cmap
score
LMS III
cmap
score
2-Deoxy-d-glucose Glycolysis inhibitor Epilepsy, optical imaging agent 0.952 0.874 0.514
MG-132
Proteasome inhibitor, JNK1
activator, and NF-κB inhibitor None −0.535 0.792 −0.981
Metformin HCl
Gluconeogenesis inhibitor,
AMPK activator
Type II diabetes, gestational diabetes, and
polycystic ovary syndrome
−0.217 0.147 0.315
LY-294002 PI3K inhibitor None −0.157 −0.085 −0.3
Sirolimus mTOR inhibitor Organ transplant rejection 0.135 −0.109 −0.155
Doxorubicin Topoisomerase II inhibitor Solid cancers, hematological cancers −0.536 −0.724 0.409
Geﬁtinib EGFR inhibitor Nonsmall cell lung cancer −0.941 −0.83 .736
Tyrphostin AG-825 EGFR inhibitor None −0.982 −0.893 0.905
6-Thioguanine Antimetabolite Acute leukemia, chronic myeloid leukemia 0.564 −0.913 0.866
Cantharidin Protein phosphatase inhibitor None −0.977 −0.931 −0.98
Oxamic acid Lactate dehydrogenase inhibitor None −0.867 −0.964 0.893
50% cell viability inhibition at a 10μM concentration. While
we found no statistically signiﬁcant association between a
signiﬁcant cmap enrichment score and inhibition of cell
viability, our data did show a trend suggesting that a highly
nonzero cmap enrichment score to LMS subtype II is more
likely to be predictive of in vitro drug response (8/21, 38% of
highly nonzero enrichment scores showed high levels of cell
viability inhibition compared with 2/12, 17% of enrichment
scores near zero (P = 0.26); Supplemental Table S3).
These ﬁndings suggest that further work that would
include a larger number of observations is needed to system-
atically evaluate the relationship between cmap enrichment
score and in vitro drug response in LMS. However, we
note that we selected a set of 11 drugs highly enriched for
enrichment scores near 1 or −1, and we did identify 2 of
11 drugs with strong in vitro activity. These drugs represent
novel candidate drugs for treatment of LMS.
3. Discussion
There are currently no targeted therapies available for the
treatment of LMS. Treatment of LMS typically consists of
surgery with doxorubicin-based chemotherapy and consid-
eration for adjuvant ifosfamide and radiotherapy in selected
cases.Doxorubicin-based therapyhasonlyshownamarginal
association with improved overall survival, thereby making
it important to evaluate additional therapeutic molecules for
the treatment of these tumors [1].
Previously, we have shown that there exist three distinct
subtypes of LMS, characterized by unique genomic, tran-
scriptional, and protein expression characteristics [2]a n dw e
hypothesized that the diﬀerences inherent to these tumor
subtypes may underlie the heterogeneity in drug responses
observed in LMS patients. Previously, gene expression pro-
ﬁles had been shown to be predictive of metastatic out-
come in LMS, suggesting that evaluating the transcriptional
features of these tumors may provide important insights
into the biology of LMS [14]. In the present work, we
performed a comparative gene expression proﬁling study
between samples from each of these three LMS subtypes and
a set of benign leiomyomas, and we used this analysis to
identify drugs predicted to turn each of the LMS subtypes
from a “malignant” to a “benign” state.
Of the 11 small molecules evaluated experimentally in
ourcurrentstudy,twodrugs,CantharidinandMG-132,were
able to strongly inhibit cell viability in all three LMS cell lines
tested. Cantharidin is an ancient Chinese medicine that has
been demonstrated to have anticancer activity through its
inhibition of protein phosphatases [10–12]. Interestingly, in
our functional gene set analysis, we previously found that all
three LMS subtypes are highly enriched for phosphoproteins
compared to the background full Homo sapiens genome [2].
The in vitro eﬃcacy demonstrated in the current work may
provide a starting point for a more rigorous in vitro and
in vivo exploration of Cantharidin or other phosphatase
inhibitors for the treatment of LMS.
MG-132 is a potent inhibitor of the proteasome with an
ability to speciﬁcally reduce the degradation of ubiquitin-
conjugated proteins in mammalian cells [13]. Proteasome
inhibitors have demonstrated clinical eﬃcacy in several can-
cers, as is evidenced by bortezomib’s 2003 FDA approval for
the treatment of relapsed multiple myeloma and mantle cell
lymphoma, and carﬁlzomib, a next-generation proteasome
inhibitor, showing promising results in mid-stage clinical
trials [15]. Given the strong eﬀect on cell viability observed
withMG-132inLMScells,weevaluatedwhetherbortezomib
(which was not included in the original cmap screen) could
similarly inhibit LMS cell viability and found that the drug
had extremely potent antigrowth eﬀects on the three LMS
cell lines evaluated. Bortezomib had previously been investi-
gatedforthetreatmentofmalignantsoft-tissuesarcomasina
21-patient Phase II clinical trial; while the authors concludedSarcoma 5
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Figure 3: Subtype speciﬁcity of LMS cell lines. The correlations of
LMS03, LMS04, and LMS05 cell lines to the centroids of the three
LMS subtypes were assessed by nearest centroid analysis (a). The
average expression levels of LMS subtype I, II, and III genes were
evaluated in the three LMS cell lines to identify which LMS subtype
these cell lines most closely resembled (b).
that bortezomib had limited activity as a single agent for the
treatment of these cancers, it is interesting to note that only
four LMS patients were included in this cohort, and that the
single conﬁrmed partial response observed in the study was
in an LMS patient [16]. Therefore, it may be worthwhile to
further investigate the clinical potential of bortezomib for
LMS treatment, either as a single agent or in combination
with other molecules with demonstrated antigrowth activity
in LMS.
Several reports in the literature have utilized com-
parative gene expression proﬁling studies between normal
and diseased tissues to identify and validate drugs with
therapeutic potential. Two such studies utilized cmap to
identify potential therapeutic molecules for neuroblastoma
and colorectal cancer [6, 7]. A similar approach was recently
used to demonstrate that topiramate, an anticonvulsant used
to treat epilepsy, showed therapeutic eﬃcacy in a preclinical
model of inﬂammatory bowel disease [16]. While these
studies highlight the potential utility of gene expression-
based approaches to help identify a molecule that can be
repurposed for novel therapeutic indications, little system-
atic analysis has been performed to evaluate the relationship
between the cmap-derived enrichment scores and the actual
responses observed in disease models; previous published
reports have focused predominantly on documenting the
positive associations discovered with little attention paid to
predicted associations that were unable to be validated in
follow-up experiments.
In the present work, we show that while using cmap
we were able to identify two drugs that potently inhibited
LMS cell growth, there was no overall statistically signiﬁcant
association between cmap enrichment scores and actual cell
viability inhibition in vitro in the 11 drugs that we tested. It
is important to note that the primary goal of our analysis
was to identify new therapeutic drugs for LMS and not to
systematically evaluate cmap, and consequently the set of
11 drugs we selected was signiﬁcantly enriched for drugs
with highly nonzero enrichment scores. This design may
have increased our ability to identify eﬀective drugs, but gave
us little statistical power to rigorously evaluate associations
between drug response and cmap score, as we evaluated few
drugs with enrichment scores near zero. The two drugs that
showed in vitro eﬃcacy showed highly divergent enrichment
scores, with Cantharidin showing a highly negative score
while MG132 showed a strongly positive score. Although our
study was not well-powered to identify signiﬁcant overall
associations between enrichment scores and in vitro eﬃcacy
in LMS, the rate at which we were able to identify drugs
that could inhibit cell viability using cmap (2/11 molecules
evaluated, or 18.4%) was higher than similarly designed
studies that screened entire chemical libraries without a
priori predictions of eﬃcacy. For example, Rickardson and
colleagues observed a 4.4% hit rate (56/1,266 molecules
evaluated) for small molecules that could inhibit myeloma
cell line growth, and Zhang and colleagues observed a 0.6%
hit rate (16/2,816 molecules evaluated) in a screen of new
therapeutic compounds that could inhibit thyroid cancer
growth [17, 18]. While our data are far from deﬁnitive
in answering the important question of cmap’s utility for
identifying eﬀective therapeutic molecules, they do suggest
that algorithmic approaches can be taken to increase the
success rate of small molecule screens.
Further, while the gene expression proﬁles of the three
LMS cell lines evaluated showed the strongest similarity
to LMS Subtype II, it is likely still necessary to evaluate6 Sarcoma
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Figure 4: In vitro cell viability assays of 11 drugs on three LMS cell lines. Three LMS cell lines, LMS03, LMS04, and LMS05, were exposed
to the indicated drugs at concentrations ranging from 0 to10μM. Cell viability was assessed 72h after exposure to drugs using WST-1 assays
and experiments were performed in triplicate. Data are arranged in order of decreasing magnitude of cmap enrichment scores for LMS
Subtype II, which all three cell lines most closely resembled according to our analysis.Sarcoma 7
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Figure 5: In vitro cell viability of LMS cell lines treated with borte-
zomib. LMS03, LMS04, and LMS05 were exposed to bortezomib at
concentrations ranging from 0 to10μM. Cell viability was assessed
72h after exposure to drugs using WST-1 assays and experiments
were performed in triplicate.
abroaderspectrumofcelllinesinordertoascertainwhether,
and to what degree, our LMS patient tumor subtyping
is applicable to immortalized cultured cells. Unfortunately,
there exist very few human LMS cell lines available for study,
therebylimitingourabilitytomorerigorouslyinvestigatethe
relationship between subtype speciﬁcity and drug response.
As more LMS clinical specimens are immortalized and made
available to the research community for cell culture studies,
it would be informative to ascertain their subtype speciﬁcity
and to characterize their drug response proﬁles.
Our ﬁndings do suggest that further work is needed
to systematically assess the relationship between cmap
enrichment scores and drug eﬀects in a variety of cancer cell
model systems. It will be valuable for future studies of drug
candidates identiﬁed using computational approaches to
documentboththe identiﬁed candidates thataresuccessfully
validated as well as the candidates that do not show eﬃcacy
in follow-up experiments.
In conclusion, we utilized gene expression proﬁles to
predict novel drug candidates for LMS, and we functionally
tested 11 of these drugs using in vitro assays. Our study
identiﬁed two drugs, Cantharidin and MG-132, that showed
strongantigrowtheﬀectsinLMScelllinesandthatmayform
the starting point for a more focused evaluation of these and
similar drugs for the treatment of LMS.
4.MaterialsandMethods
4.1. Gene Expression Proﬁling and Data Processing. The
clinico-pathologic features of the 51 LMS cases have been
described previously [2]. The 19 LM samples were reviewed
by a senior pathologist specializing in sarcoma diagnosis
to conﬁrm diagnosis based on published criteria. Total
RNA isolation, RNA labeling, and hybridization to 44K
spotted complementary DNA microarrays were carried out
using standard procedures as described previously [2]a n d
microarraydataareavailablefordownloadthroughtheStan-
ford Microarray Database (http://smd.stanford.edu/)[ 19].
Signiﬁcance Analysis of Microarrays (SAM) was performed
to identify genes diﬀerentially expressed between each of the
LMS subtypes and the leiomyoma samples [9]. We then used
SAM to determine the top 100 genes upregulated (“upsigna-
ture”) or downregulated (“downsignature”) in each of the 3
LMS subtypes compared to the 19 leiomyoma samples; these
gene lists were used for subsequent analysis.
4.2. Connectivity Map. The “upsignature” and “downsigna-
ture” generated for each of the 3 LMS subtypes were
uploaded into cmap [4, 5]. In cmap, a “perturbagen” is
deﬁned as any modality (small molecule, genetic reagent,
etc.) that can be used to treat cells and induce gene
expression changes. Each perturbagen can be represented
by 1 or multiple instances in cmap. An instance consists
of a treatment and control cell-line pair with probe sets
ordered by their extent of diﬀerential expression between
the pair. We focused our analysis on a perturbagen-centered
(ratherthaninstance-centered)analysisofthecmapdata.We
focusedouranalysisoneachperturbagen’senrichmentscore,
which is a measure of the enrichment of the perturbagen’s
instances’ connectivity scores among the ordered list of
all connectivity scores. The connectivity score is a value
between +1 and −1, and a high positive score indicates
that the perturbagen induced the expression of the query
LMS subtype signature, while a high negative score indicates
the perturbagen reversed the expression of the query LMS
subtype signature. For each treatment and control cell-line
pair(instance)incmap,theinstance’sconnectivityscorewith
each LMS subtype signature was determined. The connec-
tivity is determined by computing a Kolmogorov-Smirnov
(KS) statistic separately for the up and down components of
the LMS subtype query signatures. The connectivity score is
set to zero if the up and down KS statistics are in the same
direction, otherwise the connectivity score is the KS-up score
minus the KS-down score. The enrichment scores, which are
based on a perturbagen’s connectivity scores, is computed
for each perturbagen, and the enrichment score values are
normalized to the scale −1t o+ 1 .c m a pd o e sp r o v i d e
permutation-based P values to estimate the probability of
observing a perturbagen’s enrichment score due to chance;
however, only a minority of perturbagens in the database
contained nonnull P values, due to insuﬃcient replicates,
lessthan50%nonnullconnectivityscoresforaperturbagen’s
instances,orameanconnectivityscoreofzero.Toallowusto
use the full database of perturbagens to generate hypotheses,
we focused our analysis on perturbagen enrichment scores
and not the perturbagen P values.
4.3. Cell Culture. LMS03, LMS04, and LMS05 cell lines were
derived from human LMS clinical specimens and have been
described previously [20, 21]. LMS03, LMS04, and LMS05
weregrowninRPMI-1640media(Invitrogen)supplemented
with 10% Fetal Bovine Serum (Sigma-Aldrich) and 1%8 Sarcoma
L-glut-Pen-Strep (Gemini Bio-Products). Cells were main-
tained at 37◦C and 5% CO2 and the medium was replaced
every 2-3 days.
4.4. Drug Preparations. Doxorubicin, Cantharadin, tyro-
phostin, 6-thioguanine, oxamic acid, 2-Deoxy-d-glucose,
and DMOG were purchased from Sigma-Aldrich. MG132
was purchased from AG Scientiﬁc. Geﬁtinib and Metformin
HCl were purchased from Tocris Bioscience. LY294002 was
purchased from Cell Signaling Technology. Sirolimus was
purchased from Cayman Chemical. Bortezomib was pur-
chased from Selleck Chemicals. All drugs were reconstituted
in DMSO (Sigma-Aldrich) to create stock concentrations of
10mM.
4.5. Cell Viability Assays. Cells were seeded at a density
of 4,000 cells per well in clear 96-well plates (Techno
Plastic Products, Trasadingen, Switzerland), incubated for
24h to allow adherence to the surface, and then treated
in quadriplicate for 72h with nine-point dilution series of
the compounds. For all drugs, a concentration range of
0t o1 0 μM was used. Cell viability was determined using
the WST-1 Cell Proliferation Assay (Roche Diagnostics)
according to manufacturer’s protocols; average signals were
plotted.
4.6. Statistical Analysis. For each of the 3 LMS cell lines,
we computed the Pearson correlation between the drug’s
percent inhibition and the drug’s enrichment score. To
assess whether the magnitude (and not direction) of the
score was associated with inhibition, we used the absolute
value of the enrichment score in the correlation analysis.
To assess whether a discretized enrichment score showed
a signiﬁcant association with discretized cell viability, we
discretized the values at a threshold (0.75 for enrichment
score, 50% viability at a 10uM drug concentration for cell
viability) and computed a Fisher’s exact test.
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